We're on a mission to transform how clinical trials are designed, empowering modern teams to create better studies and bring life-changing therapies to patients faster.
Your HbA1c threshold (≥8.5%) is stricter than 89% of competing Phase 3 trials. Loosening to ≥7% could expand your eligible population by 23%.
The primary objective of this study is to evaluate the efficacy and safety of ARX-247 compared to placebo in adults with Type 2 Diabetes Mellitus.
Secondary objectives include assessment of glycemic control, cardiovascular outcomes, and patient-reported quality of life measures
Teams involved in clinical trial design generate hard-won knowledge with every trial. Most organizations lose this knowledge over time; it gets buried in inboxes, scattered across systems, or lost when people move on.
We aim to centralize all that so it is searchable, reusable, and everything stays with your organization.
Accelerators, research labs, and institutions supporting Altrovia on the way to reimagining clinical trial design.
Accelerate protocol design while reducing costly amendments across global portfolios.
Design submission-ready protocols faster, without massive internal infrastructure.
Gain competitive advantage by delivering smarter, faster trials that win sponsor trust.
Build compliant, data-driven protocols for resource-limited teams.
Make your region more competitive for global trials, by strengthening your infrastructure.
Ready to see how Altrovia fits your workflow? Let's talk.